Gene Mack
President, CEO, Director & Interim CFOMr. Gene Mack, M.B.A. is President, Chief Executive Officer & Director of Gain Therapeutics, Inc. from January 06, 2025 and was its Chief Financial Officer since April 8, 2024 until January 06, 2025 and was its Interim CEO since June 25, 2024 until January 06, 2025. Mr. Mack is Interim Chief Financial Officer of Gain Therapeutics, Inc. since October 1, 2026. Mr. Mack served as Chief Financial Officer of Imcyse SA since November 2021. He joined Imcyse SA in November 2021. He served as Chief Financial Officer of Biom’up US Inc at Biom'Up S.A. He served as Chief Financial Officer and Treasurer of SELLAS Life Sciences Group Inc. since April 20, 2018 until December 17, 2018. Mr. Mack served as Senior Director of Investor Relations at Edge Therapeutics, Inc. since April 2014 until May 2015. Previously, Mr. Mack was a Senior Biotechnology Analyst at Brean Capital LLC, Research Division from March 7, 2013 to February 2014. He covered iotechnology space within healthcare sector. He was an Equity Analyst at HSBC, Research Division and Lazard Capital Markets LLC, Research Division. Mr. Mack has experience as a senior sell-side equity Analyst covering the biotechnology, life science and specialty pharmaceutical sectors for a number of investment banking firms. His experience includes evaluation and numerous in-licensing, strategic and corporate financing transactions and the consistent publication of research for institutional Investors in biotechnology and pharmaceutical sectors. He has experience in the life sciences sector, with particular focus on capital markets, business development and corporate finance. He joined Imcyse from OncoC4, a privately held biotechnology company that spun out of MSD’s acquisition of OncoImmune. Along with orchestrating the successful transaction between the two companies, he oversaw OncoC4’s financial establishment. Before that, he was CFO for a number of development-stage and commercial-stage biopharmaceutical companies. He has a proven track record of success in the biotechnology space. Prior to transitioning to an operational CFO, he served as a senior publishing Analyst covering biotechnology and life sciences for a number of investment banks, including Gruntal & Co. Lazard and HSBC. He was an Analyst at Mizuho Securities USA Inc. Research Division. Previously, he was an Analyst at BioInvest, LLC. Mr. Mack also worked at HSBC Holdings plc, Research Division and Ryan Beck & Co. Research Division. He was an Analyst at Soleil Securities Group, Inc. and of Soleil Securities Corporation. Mr. Mack was an Equity Analyst at Gruntal & Co, Research Division. Prior to joining the sell-side, Mr. Mack completed consecutive research fellowships in biochemistry at Cornell University Medical College and clinical neurology at Columbia University College of Physicians and Surgeons. Mr. Mack received his BS in Biochemistry and MBA in Finance from Fordham University.
Positions
- Company NameGain Therapeutics, Inc.Stock CodeGANXPositionPresident, CEO, Director & Interim CFO
